Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI Study of AZD2389 with Midazolam, Caffeine, and Bupropion
NCT06973005Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD2389 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by AstraZeneca. Primary endpoints: Ratio of treatment to reference based on Cmax, Ratio of treatment to reference based on AUCinf and 2 more. Started May 2025; status: completed.
02
Drugs
AZD2389
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06973005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973005.